IRVINE, Calif. & EAST MELBOURNE, VICTORIA, Australia--(BUSINESS WIRE)--Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com)
The genetic baldness tests will be introduced to Australia by Advanced Hair Studio (AHS). The company has been offering Hair Restoration in Australia and Worldwide for 35 years. AHS has approximately 75 studios Worldwide and offers various treatments from the patented Strand by Strand procedure through to Advanced Laser Therapy.
“Our clients for Advanced Laser Treatment generally fall into the age category of 18-35 and are made up of male and female from all ethnicities,” says Carl Howell, Managing Director of AHS. “We will be offering the Hair DX test to new clients to assist them in identifying if they carry the genetic variations associated with hair loss before offering them treatment to delay the onset of symptoms.”
HairDX’s easy to use genetic test provides an accurate and understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.
“With this entry into Australia, HairDX continues as a global innovator in molecular dermatology. We’re pleased to bring the latest in genetic science to men and women in the Australia and New Zealand through AHS,” says Andy Goren, President & CEO of HairDX, LLC.
About Advanced Hair Studio
Advanced Hair Studio was founded in Australia over 35 years ago. Today they operate in 11 countries and are the market leader in the UK, Australia, New Zealand, S. Africa, Sweden, India and Ireland and provide a number of treatments and services to assist persons who suffer from hair loss including their Strand-by-Strand procedure.
About HairDX, LLC
HairDX, LLC (www.hairdx.com and Twitter: @HairDX) is a subsidiary of PharmaGenoma, Inc. Based in Irvine, CA, USA. HairDX is a molecular dermatology research and development company. HairDX markets the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual's genetic make up. HairDX uses only CLIA certified laboratories (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. The HairDX test collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device.
Among HairDX leaders is William V. Murray former Division President of the Molecular Biology Division of Applied BioSystems, Inc., who formerly served in various executive leadership positions within Medtronic, Inc., Andy Goren former CEO of MobileWise, Inc. and GeePS, Inc., Professor Doron Lancet, PhD, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Dr. Elon Pras, Director of the Institute of Human Genetics, Sheba Medical Center in Tel-Hashomer, Israel, Sharon Keene, MD and President and Medical Director of Physician's Hair Institute, in Tucson, Arizona and nationally recognized for her pioneering work in the hair transplant field, and Elliott J. Stein, an intellectual property attorney and co-founder of GeePS, Inc.